FDA comments on phase I clinical trials without vector biodistribution data.

S Epstein; S Bauer; A Miller; A Pilaro; P Noguchi

doi:10.1038/11895

Home/Archive/PubMed

PubMed · 10431234

FDA comments on phase I clinical trials without vector biodistribution data.

S Epstein·S Bauer·A Miller·A Pilaro·P Noguchi

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Clinical Trials, Phase I as Topic Genetic Therapy Genetic Vectors Germ-Line Mutation Humans Mutagenesis, Insertional Tissue Distribution United States United States Food and Drug Administration Letter

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S Epstein, S Bauer, A Miller, A Pilaro, P Noguchi. 1999. FDA comments on phase I clinical trials without vector biodistribution data.. https://doi.org/10.1038/11895

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

Much has been written recently about low productivity in the pharmaceutical industry and the high cost of drug development. Over a 10-year period ending in 2000, only approximately 11% of compounds tested in humans across 10 large pharmaceutical companies were eventually approved for marketing in the United States and/or Europe. Attrition was highest during phase II (62%) but still significant in phase III (45%) and at the time of registration (23%). Clearly, given the high cost and time required for clinical development, these late-stage failures are unsustainable.

Clinical Trials, Phase I as Topic↗

PubMed2007

Transgenic probiotica as drug delivery systems: the golden bullet?

Functional human proteins are constitutively produced in genetically modified bacteria that survive on human mucosal surfaces, to the benefit of the host. The successful Phase I clinical trial with IL-10-producing Lactococcus lactis for Crohn's disease has opened new avenues for the use of transgenic bacteria as delivery vehicles. The major advantage of this novel strategy is the avoidance of systemic side effects associated with conventional therapies. This methodology opens up an alternative method for local delivery of therapeutic proteins to various mucosal tissues.

Clinical Trials, Phase I as Topic↗

PubMed2006

Escalation, group and A + B designs for dose-finding trials.

In this paper, rules are given on how to construct escalation, A + B, and group designs for dose-finding trials. Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered.

Clinical Trials, Phase I as Topic↗